Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
1.460
-0.010 (-0.68%)
At close: Nov 20, 2024, 4:00 PM
1.470
+0.010 (0.68%)
After-hours: Nov 20, 2024, 7:59 PM EST

Company Description

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.

Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-ĸβ pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors.

It also develops ENV 105, an antibody that targets CD105/Endoglin, which expressed in tumor cells and surrounding cells; and ENV 205, an antibody that targets mitochondrial DNA.

Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016.

The company was incorporated in 2013 and is based in Los Angeles, California.

Kairos Pharma, Ltd.
Country United States
Founded 2013
IPO Date Sep 16, 2024
Industry Biotechnology
Sector Healthcare
Employees 3
CEO John Yu

Contact Details

Address:
2355 Westwood Boulevard, Suite 139
Los Angeles, California 90064
United States
Phone 310-948-2356
Website kairospharma.com

Stock Details

Ticker Symbol KAPA
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.00
CIK Code 0001962011
ISIN Number US48301N1046
Employer ID 46-2993314
SIC Code 2834

Key Executives

Name Position
Dr. John S. Yu M.D., Ph.D. Chief Executive Officer, Chairman and Secretary
Douglas W. Samuelson CPA Chief Financial Officer
Dr. Neil A. Bhowmick Ph.D. Chief Scientific Officer
Dr. Ramachandran Murali Ph.D. Vice President of Research and Development

Latest SEC Filings

Date Type Title
Nov 19, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Oct 10, 2024 8-K Current Report
Oct 4, 2024 8-K Current Report
Sep 27, 2024 S-8 Securities to be offered to employees in employee benefit plans
Sep 27, 2024 8-K Current Report
Sep 24, 2024 8-K Current Report
Sep 17, 2024 8-K Current Report
Sep 17, 2024 424B4 Prospectus
Sep 16, 2024 EFFECT Notice of Effectiveness